Drug Interactions and Safety Profiles of New CGRP-Based Migraine Medications
New anti-migraine drugs including gepants, lasmiditan, and CGRP monoclonal antibodies have distinct drug interaction profiles that clinicians must consider when prescribing.
Quick Facts
What This Study Found
Gepants and lasmiditan have significant drug interaction potential with CYP3A4 inhibitors, serotonergic drugs, and transporter inhibitors, while CGRP monoclonal antibodies have pharmacodynamic interactions related to immune modulation.
Key Numbers
7 drugs reviewed; gepants: CYP3A4/P-gp/BCRP; lasmiditan: serotonergic; mAbs: FcγR interactions
How They Did This
Review of published pharmacokinetic, pharmacodynamic, and drug interaction data for lasmiditan, gepants, and CGRP monoclonal antibodies.
Why This Research Matters
Migraine patients often take multiple medications. Understanding drug interactions prevents adverse effects and ensures these new treatments are used safely.
The Bigger Picture
As CGRP-targeting drugs become standard migraine therapy, clinicians need comprehensive drug interaction data to safely integrate them into patients' existing medication regimens.
What This Study Doesn't Tell Us
Review based on available data at time of publication. Long-term interaction data and real-world evidence still accumulating.
Questions This Raises
- ?Are there clinically significant interactions between gepants and common co-prescribed medications?
- ?How do CGRP antibody interactions differ from traditional small molecule drug interactions?
- ?Should specific drug combinations be avoided with lasmiditan?
Trust & Context
- Key Stat:
- 8 new drugs Anti-migraine medications reviewed for drug-drug interactions, spanning three distinct drug classes
- Evidence Grade:
- Review of pharmacological data from clinical trials and regulatory submissions. Reliable drug interaction information but real-world experience still growing.
- Study Age:
- Published in 2020. Additional interaction data have accumulated since then as these drugs are more widely used.
- Original Title:
- Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies.
- Published In:
- Pharmaceutics, 12(12) (2020)
- Authors:
- Szkutnik-Fiedler, Danuta
- Database ID:
- RPEP-05153
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Do new migraine drugs interact with other medications?
Yes. Gepants and lasmiditan can interact with serotonergic drugs, certain enzyme inhibitors, and drug transport proteins. CGRP antibodies have fewer traditional drug interactions but can affect immune system function.
Are CGRP antibodies safer than gepants for drug interactions?
CGRP antibodies generally have fewer drug-drug interactions because they're not processed by liver enzymes like gepants. However, they can modulate immune function through Fc gamma receptors, which is a different type of interaction concern.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05153APA
Szkutnik-Fiedler, Danuta. (2020). Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies.. Pharmaceutics, 12(12). https://doi.org/10.3390/pharmaceutics12121180
MLA
Szkutnik-Fiedler, Danuta. "Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of New Anti-Migraine Drugs-Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies.." Pharmaceutics, 2020. https://doi.org/10.3390/pharmaceutics12121180
RethinkPeptides
RethinkPeptides Research Database. "Pharmacokinetics, Pharmacodynamics and Drug-Drug Interaction..." RPEP-05153. Retrieved from https://rethinkpeptides.com/research/szkutnik-fiedler-2020-pharmacokinetics-pharmacodynamics-and-drugdrug
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.